Maxwell Burch, MD
Ophthalmology · Fort Myers, FLNPI 1174919583
Payments from drug & device makers
Across 152 payments — averaging $34.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$976
- Alcon$834
- Dompe US, Inc.$583
- Sun Pharmaceutical Industries Inc.$456
- Bausch & Lomb Americas Inc.$422
- Biotissue Holdings Inc.$376
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$5,222100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $976 |
| Alcon | 16 | $834 |
| Dompe US, Inc. | 12 | $583 |
| Sun Pharmaceutical Industries Inc. | 9 | $456 |
| Bausch & Lomb Americas Inc. | 13 | $422 |
| Biotissue Holdings Inc. | 13 | $376 |
| Amgen(2 entities) | 5 | $303 |
| Johnson & Johnson Vision Care, Inc. | 2 | $250 |
| Glaukos Corporation | 4 | $160 |
| Tarsus Pharmaceuticals, Inc. | 1 | $125 |
| Ocular Therapeutix, Inc. | 1 | $109 |
| Coopervision Inc. | 1 | $103 |
| Sight Sciences, Inc. | 5 | $85 |
| Novartis | 3 | $73 |
| Aerie Pharmaceuticals, Inc. | 4 | $71 |
| Rxsight Inc | 2 | $47 |
| Harrow Eye, LLC | 2 | $37 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $32 |
| Halozyme Inc | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Alimera Sciences, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Carl Zeiss Meditec USA, Inc. | 1 | $15 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
| Tearlab Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$477
- ReSTOR$272
- Acuvue$250
- Oxervate$246
- TEPEZZA$246
- CEQUA$246
- Precision7$136
- TRYPTYR$126
- XDEMVY$125
- INFUSE$123
- BIOTRUE ONE DAY$123
- DEXTENZA$109
- Centurion$106
- MyDay Contact Lens$103
How this compares
$5,248 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 104 | $5,267,885 |
| MieboPerfluorohexyloctane/Pf | 16 | $12,000 |
| RestasisCyclosporine | 14 | $10,528 |
| Ketorolac Tromethamine | 183 | $6,494 |
| Prednisolone Acetate | 140 | $5,313 |
| Mupirocin | 409 | $2,735 |
| Loteprednol Etabonate | 15 | $2,728 |
| MoxifloxacinMoxifloxacin Hcl | 55 | $1,249 |
| ValacyclovirValacyclovir Hcl | 35 | $1,203 |
| Latanoprost | 70 | $884 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 36 | $689 |
| Dorzolamide Hcl | 18 | $304 |
| Timolol Maleate | 17 | $142 |
| Tobramycin | 15 | $105 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $583 | $5,267,885104 claims |
| Bausch & Lomb Americas Inc.Miebo | $422 | $12,00016 claims |
| AbbVieRestasis | $976 | $10,52814 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $22 | $2,72815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Fort Myers
- Stephen SmithFort Myers$591K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.